www.hiv-druginteractions.org			University of LIVERPOOL
		Interaction Report	
Report ID:	170716		
Date Produced:	12 May 2025		
Antiretroviral Treatment		Co-medications	

Efavirenz (EFV)	Quetiapine

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see www.hiv-druginteractions.org .

## Description of the interactions

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

## Efavirenz (EFV) + Quetiapine

Coadministration has not been studied. Quetiapine is metabolised mainly by CYP3A4. Efavirenz could potentially decrease quetiapine exposure through induction of CYP3A4. Monitor side effects and increase quetiapine dosage if needed. Quetiapine has a conditional risk of QT prolongation and/or TdP on the CredibleMeds.org website. Efavirenz was shown to prolong the QT interval above the regulatory threshold of concern in homozygous carriers of the CYP2B6\*6/\*6 allele (i.e. 516T variant in the gene encoding CYP2B6). The European product label for efavirenz contraindicates coadministration with a drug with a known risk of Torsade de Pointes whereas the American product label for efavirenz recommends that alternatives should be considered. As the potential risk of a QT interval prolongation relates specifically to homozygous carriers of CYP2B6\*6/\*6 and given the accumulated years of safety data with efavirenz and such drugs, the contraindication is not reflected in the colour coding of this interaction summary.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

This report is provided for information only. It is not intended to replace a consultation with an appropriately qualified health protessional. Information presented relates only to known or suggested effects of interacting medications, and is based on relevant to the provide discussion. Information presented relates only to known or suggested effects of interacting medications, and is based on relevant to the provide discussion. Information presented relates only to known or suggested effects of interacting medications, and is based on relevant to the relation of the provide discussion. Information presented relates only to known or suggested effects of interacting medications, and is based on relevant to the relation of the relation of the provide discussion. No clinical averages with a relation of the relation of th